Jaewon Ryu
About Jaewon Ryu
Dr. Jaewon Ryu, age 51, has served on Privia Health’s Board since 2021 and is currently an independent Class II director. He is CEO of Risant Health (since April 2024; Geisinger acquisition) and previously served as President and CEO of Geisinger after joining as EVP and CMO in 2016; he holds a BA from Yale, MD and JD from the University of Chicago, and completed emergency medicine residency at Harbor‑UCLA . He is affirmatively determined independent under Nasdaq/SEC rules, and attended at least 75% of Board and committee meetings in 2024; the Board held five meetings and meets regularly in executive sessions .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Risant Health | Chief Executive Officer | April 2024–present | Leads integrated care system post‑Geisinger acquisition |
| Geisinger | President & CEO; previously EVP & Chief Medical Officer | CEO: June 2019–April 2024; EVP/CMO: Sept 2016–June 2019 | Oversaw clinical enterprise, health plan, medical school; quality/affordability improvements |
| Humana | President, Integrated Care Delivery | Prior to Geisinger (dates not specified) | Managed owned/joint‑venture care assets and MSO population health adoption |
| University of Illinois Hospital & Health Sciences System; Kaiser Permanente; CMS; VA (White House Fellow) | Various leadership roles; White House Fellow | Prior roles (dates not specified) | Government/program operations; policy exposure |
| McDermott Will & Emery | Corporate Healthcare Attorney | Prior role (dates not specified) | Legal/regulatory perspective |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Teleflex, Inc. | Director | Current (year not specified) | Public company board; medical devices sector |
| MedPAC | Commissioner | Since 2018 | Medicare payment policy advisory |
| NCQA | Director | Current (year not specified) | Quality assurance governance |
| The Commonwealth Fund | Director | Current (year not specified) | Health policy philanthropy oversight |
Board Governance
- Committee assignments: Member, Compliance Committee; the committee is chaired by Patricia Maryland and met five times in 2024 (one joint with Audit) .
- Independence: Board affirmatively determined Dr. Ryu is independent under SEC/Nasdaq standards .
- Attendance: All incumbent directors attended >75% of Board and committee meetings in 2024; Board met 5 times .
- Executive sessions: Board and committees meet regularly in executive session; independent Chair structure in place .
- Skills: Board skills matrix flags Dr. Ryu for leadership, healthcare industry, value‑based/government programs, medical professional, legal/compliance/risk, strategic planning/M&A, information security/technology, government/regulatory, corporate governance/responsibility .
Fixed Compensation
| Component | 2024 Amount |
|---|---|
| Annual Board Retainer (cash) | $75,000 |
| Committee Membership Fees (non‑chair) | $0 (chair fees only; Compliance chair $17,500—not applicable to Ryu) |
| Chair Fees | $0 (Independent Board Chair and committee chair fees paid to others) |
| Meeting Fees | None disclosed |
Performance Compensation
| Equity Type | Grant Policy | 2024 Grant Fair Value | Vesting Status (as of 12/31/2024) |
|---|---|---|---|
| RSUs (annual director grant) | RSUs equal to $200,000 divided by 30‑day trailing average price (policy) | $182,879 (ASC 718 grant‑date fair value) | 11,124 unvested RSUs outstanding |
Note: Director RSUs are time‑based; no performance metrics apply to director equity awards .
Other Directorships & Interlocks
| Company/Entity | Sector | Role/Notes |
|---|---|---|
| Teleflex, Inc. | Medical devices (public) | Director; no PRVA related‑party transaction disclosed with Teleflex |
| NCQA; The Commonwealth Fund | Nonprofit | Director; governance/quality/policy oversight |
| MedPAC | Federal advisory | Commissioner; Medicare payment advisory |
Expertise & Qualifications
- Education: BA (Yale); MD and JD (University of Chicago); emergency medicine residency (Harbor‑UCLA) .
- Operating experience: Led integrated delivery/health plans; MSO/population health adoption at Humana; multi‑stakeholder coordination .
- Regulatory/policy: CMS/VA fellowships; MedPAC commissioner; governance at NCQA/Commonwealth Fund .
- Board skills: Medical professional; value‑based care/government programs; strategic planning/M&A; compliance/risk; technology/security .
Equity Ownership
| Measure | Value |
|---|---|
| Total beneficial ownership (shares) | 19,127 |
| Shares outstanding (record date) | 121,313,431 |
| Ownership as % of shares outstanding | ~0.0158% (19,127 ÷ 121,313,431; computed) |
| Unvested RSUs | 11,124 (as of 12/31/2024) |
| Hedging/Pledging | Prohibited for directors under Insider Trading Compliance Policy |
| Director ownership guidelines | 5× annual cash Board retainer; all directors compliant or within 5‑year window |
Governance Assessment
- Positives: Independent director with deep clinical and policy expertise; member of Compliance Committee (healthcare compliance oversight); strong attendance; robust anti‑hedging/anti‑pledging and stock ownership guidelines enhance alignment .
- Compensation alignment: Director pay balanced between modest cash retainer and time‑based RSUs; program unchanged in 2024; no meeting fees or option grants; no tax gross‑ups; clawback policies robust for incentive compensation (company‑wide) .
- Potential conflicts: External roles include CEO of Risant Health and director at Teleflex; Company discloses no related‑party transactions involving Dr. Ryu; Audit Committee reviews related‑party matters under stated policy .
- Engagement signals: Board conducts regular executive sessions and shareholder outreach; independent Chair participates in engagements; classified board rationale disclosed and supported by investor feedback .
- RED FLAGS: None disclosed specific to Dr. Ryu (no pledging/hedging, no related‑party transactions, no low attendance). Section 16 compliance issues noted in 2024 pertained to late Forms 4 for annual RSU grants to NEOs (human error), not to Dr. Ryu .
Insider Trades (disclosed in proxy)
| Item | Disclosure |
|---|---|
| Section 16(a) compliance | Company states 2024 filings were timely except three late Forms 4 (annual RSU grants to NEOs) and one amended Form 3; no late filings identified for Dr. Ryu in proxy |
Company‑wide policies: Anti‑hedging and anti‑pledging apply to directors; director service limits and independent committees reinforce governance quality .